Endocrine Abstracts

Background: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, demonstrating durable responses, but can result in immune-related adverse events (irAEs). Endocrinopathies are amongst the more common adverse events, and thyroid dysfunction and hypophysitis being the most frequent; the latter of these has been positively correlated with oncological outcome. This study compared overall survival (OS), progression-free survival (PFS) and disease c...

Background: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, demonstrating durable responses, but can result in immune-related adverse events (irAEs). Endocrinopathies are amongst the more common adverse events, and thyroid dysfunction and hypophysitis being the most frequent; the latter of these has been positively correlated with oncological outcome. This study compared overall survival (OS), progression-free survival (PFS) and disease c...

: Recent Phase 3 studies have demonstrated the clinical utility of immunotherapy with inhibitors of PD1 in cancers, including melanoma and non-small cell lung cancer. Autoimmune side effects are common. Both hypothyroidism and hyperthyroidism have been observed in up to 16% of patients. We report for the first time the endocrine evaluation of patients with anti-PD1 induced thyroid dysfunction.Methods: All patients treated in published trials of anti-PD1 ...

Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor that improves survival in advanced melanoma. However, ipilimumab induces immune-related adverse events including hypophysitis and hypopituitarism. We describe one of the largest single centre series of ipilimumab induced hypophysitis.Methods: We retrospectively analysed all patients (n=301) treated with ipilimumab either as a monotherapy or in combination with nivolu...